These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21474967)

  • 21. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
    Niho S; Kubota K; Goto K; Yoh K; Ohmatsu H; Kakinuma R; Saijo N; Nishiwaki Y
    J Clin Oncol; 2006 Jan; 24(1):64-9. PubMed ID: 16382114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
    Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
    Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
    Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
    Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.
    Han JY; Lee SH; Yoo NJ; Hyung LS; Moon YJ; Yun T; Kim HT; Lee JS
    Clin Cancer Res; 2011 Mar; 17(6):1553-60. PubMed ID: 21411446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
    Chiu CH; Tsai CM; Chen YM; Chiang SC; Liou JL; Perng RP
    Lung Cancer; 2005 Jan; 47(1):129-38. PubMed ID: 15603863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
    Omuro AM; Kris MG; Miller VA; Franceschi E; Shah N; Milton DT; Abrey LE
    Cancer; 2005 Jun; 103(11):2344-8. PubMed ID: 15844174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
    Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib in advanced non-small cell lung cancer.
    Sharma R; Boyer M; Clarke S; Millward M
    Intern Med J; 2005 Feb; 35(2):77-82. PubMed ID: 15705135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
    Maruyama R; Nishiwaki Y; Tamura T; Yamamoto N; Tsuboi M; Nakagawa K; Shinkai T; Negoro S; Imamura F; Eguchi K; Takeda K; Inoue A; Tomii K; Harada M; Masuda N; Jiang H; Itoh Y; Ichinose Y; Saijo N; Fukuoka M
    J Clin Oncol; 2008 Sep; 26(26):4244-52. PubMed ID: 18779611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
    Reck M; Gatzemeier U
    Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.
    Wataya H; Okamoto T; Maruyama R; Seto T; Yamazaki K; Tagawa T; Fukuyama S; Osoegawa A; Ikeda J; Nishimura M; Yamanaka T; Ichinose Y
    Lung Cancer; 2009 Jun; 64(3):341-5. PubMed ID: 18995926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
    Liam CK; Pang YK; Leow CH
    Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
    van Puijenbroek R; Bosquée L; Meert AP; Schallier D; Goeminne JC; Tits G; Collard P; Nackaerts K; Canon JL; Duplaquet F; Galdermans D; Germonpré P; Azerad MA; Vandenhoven G; De Greve J; Vansteenkiste J
    Eur Respir J; 2007 Jan; 29(1):128-33. PubMed ID: 17005582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
    Shah NT; Miller VA
    Clin Lung Cancer; 2003 Nov; 5(3):182-6. PubMed ID: 14667275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
    Wu C; Li YL; Wang ZM; Li Z; Zhang TX; Wei Z
    Lung Cancer; 2007 Sep; 57(3):359-64. PubMed ID: 17434236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.